SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

NEUROPHARMACOLOGY: DRUG EFFECTS ON THE NERVOUS SYSTEM

Ms. Pramila Chaugule[1], Dr. A. R. Aswar[2]
Research Scholar[1], Research Guide[2]
H.S.B.P.V.T's Group of Institute, Faculty of Pharmacy, Kashti, Maharashtra,414701[1,2]

ABSTRACT
Neuropharmacology explores how drugs influence the nervous system and their potential in treating neurological and psychiatric disorders. This review provides a comprehensive overview of the mechanisms through which various drugs impact neural processes and their therapeutic applications. It covers major drug classes, including antipsychotics, antidepressants, anxiolytics and neuroprotective agents, highlighting their modes of action, efficacy and limitations. Advances in drug development, such as targeted therapies and novel compounds, are discussed about their potential to improve the treatment outcomes for disorders such as schizophrenia, depression, anxiety and neurodegenerative diseases. Understanding these mechanisms is crucial for developing more effective and safer treatments.
KEYWORDS: *Drug Mechanisms, Neurological Disorders, Neuropharmacology, Psychiatric Disorders, Therapeutic Innovations*

INTRODUCTION

Neuropharmacology, the study of how drugs affect the nervous system, is integral to advancing treatments for neurological and psychiatric disorders. Information is sent across the body through a specialized network of neurons. This field is important for understanding the mechanisms underlying drug actions, developing new therapies for neurological and psychiatric disorders and optimizing treatment strategies. There are some core principles of neuropharmacology Neurotransmitter systems, Neurotransmitters, Receptor interactions, Pharmacokinetics and pharmacodynamics, Blood-brain barrier, Neuroplasticity etc.

The neuropharmacology is related to two words. The neuro related to neurons in brain and pharmacology is concerned with study of drugs. Neuropharmacology is the study of neurotransmitters, neuromodulators, and their effect on the brain, most importantly the central nervous system. The history of neuropharmacology is started with just four drugs and now innumerable drugs are approved being available in clinical practices for neurologist. Drugs achieve their effects by either mimicking natural neurotransmitters to activate neurons, causing neurons to release more neurotransmitters, or by blocking their reuptake.

To understand the potential advances in medicine that neuropharmacology can bring, it is important to understand how human behavior and thought processes are transferred from neuron to neuron and how medications can alter the chemical foundations of these processes. Once the neurotransmitter is released into the synapse, it can either bind to receptors on the post-synaptic cell, the pre-synaptic cell can re-uptake it and save it for later transmission, or it can be broken down by enzymes in the synapse specific to that certain neurotransmitter. These three different actions are major areas where drug action can affect communication between neurons

How Drugs Affect the Nervous System

Drugs influence neuronal communication by targeting neurotransmitter systems:

- **Mimicking Neurotransmitters:**
  Some drugs have chemical structures similar to natural neurotransmitters and can activate neurons by attaching to them.
- **Modulating Neurotransmitter Release:**
  Other drugs can cause neurons to release abnormally large amounts of neurotransmitters or prevent the normal reuptake of these chemicals, amplifying or disrupting normal neuronal communication.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal



Antidepressants

Antidepressants primarily target neurotransmitter systems to alleviate the symptoms of depression. Selective serotonin reuptake inhibitors such as fluoxetine and sertraline enhance serotonin levels in the brain by inhibiting its reuptake. Similarly, serotonin-norepinephrine reuptake inhibitors such as venlafaxine increase serotonin and norepinephrine availability. These medications have significantly improved outcomes for many patients but are not without limitations, including delayed onset of effects and potential side effects such as weight gain and sexual dysfunction. Novel antidepressants, such as ketamine and psychedelic compounds, offer new mechanisms of action and are under investigation for their rapid and sustained antidepressant effects. The mechanism of the action of antidepressants has not been completely explained yet.

It is believed that depressive states result from the decreased activity of adrenergic and/or serotoninergic neurons, while manic states are related to the excessive stimulation of adrenergic and dopaminergic neurons, and, according to other research, to the inhibition of the activity of serotoninergic neurons. Changes in the sensitivity and number of adrenergic and serotoninergic receptors are also considered when trying to determine the pathogenesis of depression

Antipsychotics

Antipsychotic drugs are critical in managing the symptoms of schizophrenia and other psychotic disorders. Typical antipsychotics, such as haloperidol, primarily antagonise dopamine D2 receptors, which helps reduce psychotic symptoms but can lead to extrapyramidal side effects. Atypical antipsychotics, such as clozapine and risperidone, target both dopamine and serotonin receptors, offering benefits in reducing symptoms with a lower risk of motor side effects. However, concerns about metabolic side effects and long-term safety remain. Ongoing research aims to develop drugs with improved efficacy and tolerability profiles, focusing on novel targets and pathways.

Anxiolytics

Benzodiazepines, such as diazepam and lorazepam, are widely used for their anxiolytic properties. They enhance GABA-A receptor activity, leading to increased inhibition of neuronal firing and reduced anxiety. While effective for short-term management, their long-term use is limited by risks of dependency and tolerance. Non-benzodiazepine anxiolytics, such as buspirone, offer an alternative mechanism by modulating serotonin receptors, providing a lower risk of addiction but with potentially slower onset of effects. Research into new anxiolytics aims to find drugs with rapid onset and minimal side effects.

Alzheimer's Disease

While there are a variety of hypotheses that have been proposed for the cause of Alzheimer's disease, the knowledge of this disease is far from complete to explain, making it difficult to develop methods for treatment. In the brain of Alzheimer's patients, both neuronal nicotinic acetylcholine (nACh) receptors and NMDA receptors are known to be down-regulated. Thus, four anticholinesterases, such as Donepezil and Rivastigmine, have been developed and approved by the U.S. Food and Drug Administration (FDA) for the treatment in the U.S.A. However, these are not ideal drugs, considering their side-effects and limited effectiveness. The excessive stimulation of muscarinic and nicotinic receptors by acetylcholine may contribute to the side effects that anticholinesterases have.

Parkinson's Disease

Parkinson's disease is a neurodegenerative disease described by the selective loss of dopaminergic neurons located in the substantia nigra. Today, the most commonly used drug to combat this disease is levodopa or L-DOPA. This precursor to dopamine can penetrate through the blood–brain barrier, whereas the neurotransmitter dopamine cannot. There has been extensive research to determine whether L-dopa is a better treatment for Parkinson's disease rather than other dopamine agonists

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

Neuroprotective Agents

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, benefit from drugs that protect neuronal integrity and function. For instance, cholinesterase inhibitors such as donepezil improve cognitive function in Alzheimer's disease by increasing acetylcholine levels. Parkinson's disease treatments, including dopamine agonists and levodopa, help manage motor symptoms but do not halt disease progression. Emerging neuroprotective agents are being investigated for their potential to slow or reverse neurodegeneration, focusing on oxidative stress, neuroinflammation and cellular repair mechanisms.



Applications of Neuropharmacology

Neuropharmacology has a wide range of applications, particularly in treating neurological and psychiatric disorders. Key applications include.

1. **Mental health disorders:** Neuropharmacology plays a central role in developing and optimizing treatments for mental health conditions such as depression, bipolar disorder, anxiety and schizophrenia.
2. **Neurological disorders:** Parkinson's disease drugs like levodopa and dopamine agonists are used to manage motor symptoms by enhancing dopaminergic activity. Alzheimer's disease neuro enhancers and NMDA receptor antagonists help manage symptoms and slow disease progression.
3. **Pain management**: Neuropharmacology informs the development of both opioid and non-opioid analgesics, targeting various pain pathways and receptor systems to provide effective pain relief.
4. **Epilepsy:** Antiepileptic drugs are essential for controlling seizures and improving the quality of life for individuals with epilepsy.
5. **Addiction and substance abuse:** Neuropharmacological mechanisms of addiction aids in developing treatments for substance use disorders and managing withdrawal symptoms.

Neurotransmitter	Major Function	Associated Disorders	Drugs Affecting System
Dopamine	Movement, reward, motivation	Parkinson's, Schizophrenia	Levodopa, Haloperidol
Serotonin	Mood, sleep, appetite	Depression, Anxiety	SSRIs, Buspirone
GABA	Inhibition, relaxation	Epilepsy, Anxiety	Benzodiazepines, Barbiturates
Acetylcholine	Memory, attention	Alzheimer's Disease	Donepezil, Rivastigmine
Glutamate	Excitation, learning	ALS, Epilepsy	Memantine, Ketamine

Table 1. Neurotransmitter Systems and Associated Disorders

CONCLUSION

Neuropharmacology is a dynamic and vital field of study that focuses on the interactions between drugs and the nervous system. Neuropharmacology continues to evolve with advances in drug development and a deeper understanding of brain function. While current therapies have improved the management of neurological and psychiatric disorders, challenges remain in terms of efficacy, safety and side effects. Future research is expected to bring new insights and innovations, offering hope for more effective and targeted treatments. By advancing our knowledge of drug mechanisms and refining therapeutic strategies, neuropharmacology holds the potential to significantly enhance the patient outcomes and quality of life.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

REFERENCES

1. *Mishra, Vaishnavi H; Khade, Ajay[1]; Noman, Obaid[2] ,"Drug Effects on the Nervous System: Mechanisms and Future Directions in Neuropharmacological Therapy" Advances in Human Biology 10.4103/aihb.aihb_166_24, November 15, 2024. | DOI: 10.4103/aihb.aihb_166_24*
2. *Hendry Devanne, Department of Pharmacology, University of Burgundy, Dijon, France, J Pharma Reports, Vol.8 Iss.2 No:1000218*
3. *Mahnoor Amjad Butt, Pervez Anwar et-al, "Neuropharmacological Consequences of Variant Drugs" International Journal of Medical Research & Health Sciences, 2017, 6(11): 195-204, ISSN No: 2319-5886*
4. *Deba S, Research Centre of Neurology, "Neuropharmacology: Understanding the Complex Interplay of Drugs and the Nervous System" Volume 7, Issue 3, 1000142*
5. *Lepeta K, Lourenco MV, Schweitzer BC, Martino Adami PV, Banerjee P, Catuara-Solarz S, et al. Synaptopathies: Synaptic dysfunction in neurological disorders – A review from students to students. J Neurochem 2016;138:785–805.*
6. *Yeung AWK, Tzvetkov NT, Atanasov AG. When Neuroscience Meets Pharmacology: A Neuropharmacology Literature Analysis. Front Neurosci. 2018 Nov 16;12:852. doi: 10.3389/fnins.2018.00852.*
7. *Everitt, B. J.; Robbins, T. W.* (2005). "Neural systems of reinforcement for drug addiction: from actions to habits to compulsion". Nature Neuroscience. **8** (11): *1481–1489. doi:10.1038/nn1579. PMID 16251991*
8. *Shankar, et-al. World Journal of Pharmacy and Pharmaceutical Sciences, "NEUROPHARMACOLOGY" Vol 4, Issue 06, 2015. Page no.318*